Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep;11(9):1965-1982.
doi: 10.1007/s13300-020-00894-y. Epub 2020 Jul 28.

A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus

Sanjay Kalra  1 , Rakesh Sahay  2
Affiliations
Review

A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus

Sanjay Kalra et al. Diabetes Ther. 2020 Sep.

Abstract

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a well-established class of glucose-lowering drugs. GLP-1 RAs can be classified according to their structure, duration of action and mode of administration. This review describes the basic and clinical pharmacology of orally administered semaglutide. It highlights the PIONEER clinical trial programme results, and reviews the efficacy, safety and tolerability.

Keywords: GLP-1 RA; GLP-1 receptor agonists; Glucagon-like peptide; Orally administered semaglutide; Pioneer trial.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Structure of semaglutide (subcutaneous formulation)
Fig. 2
Fig. 2
Structure of SNAC
Fig. 3
Fig. 3
Estimated mean semaglutide plasma concentration–time profile after a single dose of orally administered semaglutide 10 mg [26]
Fig. 4
Fig. 4
Mechanism of absorption of semaglutide and SNAC co-formulation tablet
See this image and copyright information in PMC

References

    1. International Diabetes Federation . IDF diabetes atlas. 9. Brussels: International Diabetes Federation; 2019. - PubMed
    1. Roglic G, Unwin N, Bennett PH, et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care. 2005;28(9):2130–2135. - PubMed
    1. World Health Organization. Global status report on noncommunicable diseases, 2014. https://www.who.int/nmh/publications/ncd-status-report-2014/en/. Accessed May 31, 2020. - PubMed
    1. Lau DC, Teoh H. Benefits of modest weight loss on the management of type 2 diabetes mellitus. Can J Diabetes. 2013;37(2):128–134. - PubMed
    1. Kalra S. Diabesity. J Pak Med Assoc. 2013;63(4):532–534. - PubMed

LinkOut - more resources